Saturday 17 October 2026 Export SRPT’s income statement to Excel — free account

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

17.06 0.73 −4.10%

Follow SRPT

Alert me

Market cap: $1.9B
P/E: 0.0×
Fwd P/E: 4.4×
Dividend yield: —
F-score: 3/9
Altman Z: −0.97
Beneish M: −3.41
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio Full definition →	+8 more quarters Free account	0.00	0.00	35.27	0.00
P/S ratio Full definition →		0.80	0.98	1.05	0.96
P/FCF ratio Full definition →		0.00	0.00	21.11	25.27
P/Operating CF Full definition →		(132.44)	16.42	(11.27)	9.61
P/B ratio Full definition →		1.46	1.89	1.52	1.24
Price to Tangible BV Full definition →		1.48	1.91	1.53	1.25
EV/Sales Full definition →		0.91	0.97	1.17	1.04
EV/EBITDA Full definition →		0.00	0.00	9,628.22	0.00
EV/Operating CF Full definition →		(9.02)	(10.39)	14.61	18.43
EV/FCF Full definition →		(5.68)	(6.77)	23.66	27.28
Quick Ratio Full definition →		1.35	1.22	2.10	2.32
Current Ratio Full definition →		2.95	2.32	4.63	4.42
Net Debt/EBITDA Full definition →		(2.14)	0.27	0.50	2.59
Debt/Assets Full definition →		29.63%	24.75%	26.37%	26.58%
Debt/Equity Full definition →		0.78	0.73	0.56	0.55
Asset Turnover Full definition →		0.68	0.60	0.66	0.57
Operating CF/Net income Full definition →		0.08	(0.46)	(0.61)	(40.30)
Capex/Depreciation Full definition →		(1.66)	(0.77)	(0.31)	(0.06)
Research and Development Expense of Revenue Full definition →		54.81%	73.45%	21.07%	22.74%
Selling, General and Administrative Expense of Revenue Full definition →		23.01%	28.97%	14.91%	26.82%
Intangible Assets out of Total Assets Full definition →		0.00	0.00	0.00	0.00
Share Based Compensation of Revenue Full definition →		3.74%	6.78%	4.02%	6.10%
Graham Net Nets Full definition →		0.28	0.15	0.28	0.30
Graham Number Full definition →		0.00	0.00	14.11	0.00
Earnings Yield Full definition →		(14.22%)	(33.15%)	2.84%	(8.03%)
Free Cash Flow Yield Full definition →		(20.13%)	(14.64%)	4.74%	3.96%
Revenue per Share Full definition →		3.98	4.42	6.96	3.81
Operating CF per Share Full definition →		(0.15)	1.31	(1.93)	1.87
Capex per Share Full definition →		(0.29)	(0.04)	(0.03)	(0.01)
Free Cash Flow per Share Full definition →		(0.43)	1.27	(1.96)	1.86
Cash per Share Full definition →		8.49	9.39	6.22	7.48
Shareholders Equity per Share Full definition →		13.17	11.39	14.34	14.49
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		13.17	11.39	14.34	14.49
Free Cash Flow Full definition →		(43.26)	127.48	(205.76)	196.52
Working Capital Full definition →		1,800.88	1,442.65	1,810.71	1,720.92
Capital Expenditures Full definition →		(28.67)	(3.73)	(3.08)	(0.55)
Net Current Asset Value Full definition →		548.99	328.86	636.04	563.11
EV/EBIT Full definition →		0.00	0.00	0.00	0.00
Capex to Sales Full definition →		0.07	0.01	0.00	0.00
Price to Operating Income Full definition →		0.00	0.00	0.00	0.00
Other line items
Average Receivables Full definition →		415.13	500.11	527.09	452.06
Average Payables Full definition →		106.39	247.64	113.24	93.84
Average Inventory Full definition →		821.55	832.35	971.27	949.15
Average Assets Full definition →		3,546.69	3,656.44	3,322.16	3,434.16
Average Common Equity Full definition →		1,270.60	1,334.18	1,323.91	1,442.59

Show all line items

Columns are period end dates

Stockrow Weekly